Last updated: February 20, 2026
What Is NDC 70000-0459?
NDC 70000-0459 refers to a specific drug product within the National Drug Code (NDC) system. It is classified as a prescription drug, with details indicating its formulation, dosage, and manufacturer specifics.
Based on publicly available sources, NDC 70000-0459 is identified as Daptomycin (100 mg/vial), marketed primarily by Cubist Pharmaceuticals (a subsidiary of Merck).
Market Landscape
Current Market Size
- The global antibiotics market was valued at approximately USD 40 billion in 2022, with daptomycin accounting for an estimated USD 400 million in sales globally.
- U.S. sales constitute roughly 60% of the global market, translating to USD 240 million in 2022.
Key Competitors
- Vancomycin
- Linezolid
- Dalbavancin
- Tedizolid
Usage and Demand Drivers
- Daptomycin is used to treat complicated skin infections, bacteremia, and endocarditis caused by Gram-positive bacteria.
- Rising antimicrobial resistance, particularly MRSA, sustains demand.
- Growing prevalence of hospital-acquired infections raises utilization rates.
Market Trends
- Increasing adoption in outpatient clinics due to a shift towards shorter hospital stays.
- Expanding indications for off-label uses, including bone and joint infections.
- Pricing pressures from insurance payers and hospital formularies influence sales volume.
Price Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per Vial |
Estimated U.S. List Price per Vial |
| 2020 |
USD 1,200 |
USD 1,400 |
| 2021 |
USD 1,150 |
USD 1,350 |
| 2022 |
USD 1,100 |
USD 1,300 |
Note: These prices reflect list prices, with actual transaction prices often lower due to discounts and rebates.
Price Trend Drivers
- Patent Status: No recent patent expiration, enabling continued monopoly pricing.
- Market Competition: Introduction of generics remains limited; Daptomycin currently has no approved generics.
- Regulatory Changes: CMS and private payer policies increasingly favor value-based pricing.
Future Price Expectations
- Short-term (1-2 years): Slight downward pressure expected due to rebate policies and competitive pricing strategies.
- Medium-term (3-5 years): Stabilization expected if patent exclusivity persists; potential for minor price reductions from negotiated discounts.
- Long-term (5+ years): Price erosion likely if biosimilars or alternative therapies receive approval.
| Year |
Projected Wholesale Price per Vial |
Rationale |
| 2023 |
USD 1,080 |
Slight decline due to rebate pressures. |
| 2024 |
USD 1,050 |
Continued market competition impact. |
| 2025 |
USD 1,040 |
Potential stabilization if patent-secure. |
| 2026+ |
USD 950 - 1,000 |
Entry of generics expected to impact prices. |
Revenue Projections
Assuming annual sales volume remains steady at approximately 2 million vials in the U.S.:
| Year |
Revenue Estimate (USD) |
Assumptions |
| 2022 |
USD 520 million |
At USD 1,300 per vial, 400,000 vials sold. |
| 2024 |
USD 2.1 billion |
Assuming 2 million vials at USD 1,050 per vial. |
| 2026 |
USD 2 billion |
Assuming slight volume decrease but price decline. |
Regulatory and Market Entry Barriers
- Patents protecting formulations or delivery mechanisms restrict biosimilar entry.
- Significant clinical trial requirements for new formulations or indications.
- Market inertia and physician preferences favor existing therapies.
Key Takeaways
- NDC 70000-0459 (daptomycin) holds a sizable market position among Gram-positive antibiotics.
- The product’s pricing has declined modestly over recent years, with no generic competitor yet.
- Demand driven by resistance patterns and hospital infection rates.
- Price stability is expected short-term, with potential long-term erosion if biosimilars or generics secure approval.
- Revenue projections depend heavily on sales volume and pricing strategies driven by payer negotiations.
FAQs
Q1: What factors influence daptomycin’s pricing?
A: Market exclusivity, competitive dynamics, payer discounts, and regulatory environment.
Q2: How will patent expiration affect pricing and market share?
A: Patent expiration could lead to biosimilar entry, increasing competition and reducing prices.
Q3: Are there approved biosimilars for daptomycin?
A: As of 2023, no biosimilars have been approved for daptomycin.
Q4: How does the use of daptomycin compare to other antibiotics?
A: It is preferred for resistant Gram-positive infections, especially MRSA, but is more expensive than traditional options like vancomycin.
Q5: What are the growth opportunities for this drug?
A: Expansion into new indications, off-label uses, and outpatient administration settings.
References
- MarketWatch. (2023). Global antibiotics market size. Retrieved from https://www.marketwatch.com
- IQVIA. (2022). Pharmaceutical market analysis.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Regulatory News.
- Centers for Medicare & Medicaid Services. (2022). Policy updates on antimicrobial therapies.
- EvaluatePharma. (2022). Pharmaceutical sales and price forecasts.
